This year’s theme is the science and strategy of early drug development: what succeeds and what to avoid. Our aim is to promote innovation through lateral thinking by creating an open atmosphere for exchanging knowledge between industry, academia and the regulators.
Which development models are supportive of innovation? What can you take away from a failed study and how can it inform your next decisions? And how can you get the most out of your early phase studies?
With brand new formats, increased audience participation and an exceptional speaker faculty, Phase I & IIa Clinical Trials is a must attend event for early phase clinical professionals.
35 Sessions and 2 Carefully Tailored Streams, with Highlights Including.....
Exploring EU, USA & Canadian regulatory frameworks which support expedited drug development.
Discussing how to optimise the use of legacy data and capitalise on Big Data...
Debating the effectiveness of model-based drug development to inform go & no-go decisions.
Optimising early phase development in oncology.
Examining key operational and ethical considerations for Phase I & IIa trials in patients.
Prices from : £999 see website for full T&Cs
Sign in to add slides, notes or videos to this session